公开(公告)号：EP2778222B1

公开(公告)日：2017-03-22

申请号：EP13167122.4

申请日：2012-03-31

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： Pei, Duanqing ,  Wang, Tao

IPC分类号： C12N5/071 ,  C12N5/10

CPC分类号： C12N5/0662 ,  C12N5/0696 ,  C12N2500/38 ,  C12N2501/602 ,  C12N2501/72 ,  C12N2506/13 ,  C12N2510/00

公开(公告)号：EP2647700B1

公开(公告)日：2017-03-15

申请号：EP12801798.5

申请日：2012-03-31

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： PEI, Duanqing ,  WANG, Tao

IPC分类号： C12N5/10 ,  C12N5/071

CPC分类号： C12N5/0662 ,  C12N5/0696 ,  C12N2500/38 ,  C12N2501/602 ,  C12N2501/72 ,  C12N2506/13 ,  C12N2510/00

公开(公告)号：EP2778222A1

公开(公告)日：2014-09-17

申请号：EP13167122.4

申请日：2012-03-31

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： Pei, Duanqing ,  Wang, Tao

IPC分类号： C12N5/071 ,  C12N5/10

CPC分类号： C12N5/0662 ,  C12N5/0696 ,  C12N2500/38 ,  C12N2501/602 ,  C12N2501/72 ,  C12N2506/13 ,  C12N2510/00

摘要： The present invention relates to a method for increasing the efficiency of inducing pluripotent stem cells, and more particularly, to a method for increasing the efficiency of inducing pluripotent stem cells by utilizing genes Jhdm1a that modify histone. By utilizing Jhdm1a, and a stem cell inducing factor, the present invention increases the efficiency of inducing pluripotent stem cells and increases the quality of induced pluripotent stem cells. The stem cell inducing factor is a combination of Oct4 and Klf4, or a combination of Sox2, Oct4, and Klf4, or a combination of Oct4 and Sox2, and Oct4 alone. The method of the present invention further comprises exposing the cells to vitamin C, which further increases the efficiency of inducing pluripotent stem cells as compared with the case where no vitamin C is used. By using less stem cell reducing factors, the method of the present invention reduces the potential carcinogenicity, obtains a high inducing efficiency, and provides high-quality induced pluripotent stem cells capable of germ-line transmission.

摘要翻译： 本发明涉及提高多能干细胞诱导效率的方法，更具体地说，涉及通过利用修饰组蛋白的基因Jhdm1a来提高诱导多能干细胞的效率的方法。 通过利用Jhdm1a和干细胞诱导因子，本发明增加诱导多能干细胞的效率并增加诱导多能干细胞的质量。 干细胞诱导因子是Oct4和Klf4的组合，或Sox2，Oct4和Klf4的组合，或Oct4和Sox2以及Oct4的组合。 与不使用维生素C的情况相比，本发明的方法还包括将细胞暴露于维生素C，这进一步提高了诱导多能干细胞的效率。 通过使用较少的干细胞减少因子，本发明的方法降低潜在致癌性，获得高诱导效率，并提供能够进行种系传播的高质量诱导多能干细胞。

公开(公告)号：EP2594567A1

公开(公告)日：2013-05-22

申请号：EP11800049.6

申请日：2011-06-03

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： DING, Ke ,  WANG, Deping ,  PEI, Duanqing ,  ZHANG, Zhang ,  SHEN, Mengjie ,  LUO, Kun ,  FENG, Yubing

IPC分类号： C07D403/12 ,  C07D401/12 ,  C07D239/42 ,  C07D471/04 ,  C07D487/04 ,  A61K31/506 ,  A61K31/519 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/496 ,  A61P35/00 ,  A61P35/02

摘要： The heterocyclic alkynyl benzene compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in preparing drugs for preventing or treating tumors. The compounds can overcome the clinically induced resistance against Gleevec.

摘要翻译： 式（I）的杂环炔基苯化合物，其药学上可接受的盐和立体异构体，以及用于制备用于预防或治疗肿瘤的药物的应用。 这些化合物可以克服临床上对Gleevec的抵抗力。

公开(公告)号：EP3712260A1

公开(公告)日：2020-09-23

申请号：EP18877609.0

申请日：2018-11-13

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： LI, Yi ,  ZHOU, Peipei

IPC分类号： C12N5/22 ,  A61K39/00 ,  A61P31/00 ,  A61P35/00

摘要： Provided is a genetically engineered γδT cell, which is characterized in that a high-affinity αβTCR gene is transferred into the γδT cell, and the affinity of the high-affinity αβTCR to the specific pMHC thereof is at least two times of that of a wild-type αβTCR corresponding thereto. Further provided are a use of and a preparation method for the γδT cell.

公开(公告)号：EP3225619A1

公开(公告)日：2017-10-04

申请号：EP15863532.6

申请日：2015-11-18

申请人： Shanghai Institute Of Materia Medica Chinese Academy of Sciences ,  Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： DING, Ke ,  DING, Jian ,  CHAN, Shingpan ,  GENG, Meiyu ,  REN, Xiaomei ,  XIE, Hua ,  TU, Zhengchao ,  CHEN, Yi

IPC分类号： C07D239/48 ,  C07D401/02 ,  C07D403/12 ,  C07D239/47 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00 ,  A61P35/02

CPC分类号： C07D403/12 ,  A61K31/4523 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/551 ,  C07D239/47 ,  C07D239/48 ,  C07D401/02 ,  C07D401/12

摘要： Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.

摘要翻译： 公开了2-氨基嘧啶化合物和药物组合物及其用途。 2-氨基嘧啶化合物的结构如式I所示，在结构式中，R 1，R 2，R 3，R 4，R 5，X，Y，Z，W，（i）如说明书和权利要求书中所定义。 这类化合物能有效抑制多种肿瘤细胞的生长，对EGFR和IGF1R蛋白酶具有抑制作用，可用于制备抗肿瘤药物，克服现有药物如吉非替尼，厄洛替尼等引起的耐受性。 该化合物对肿瘤具有选择性，特别是野生型非小细胞肺癌，并具有良好的药代动力学特征。

公开(公告)号：EP3067416A1

公开(公告)日：2016-09-14

申请号：EP14860811.0

申请日：2014-08-25

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： LIU, Xingguo ,  PEI, Duanqing ,  LIU, Jinglei ,  LIU, Xuebin ,  YAO, Deyang

IPC分类号： C12N5/10 ,  C12N15/85 ,  C12N5/071

CPC分类号： C12N5/0645 ,  C12N15/87 ,  C12N2510/00

摘要： The present disclosure provides a method for producing a cell with exogenous mitochondria by obtaining synthetic mitochondria via introduction of exogenous mitochondrial DNA into mitochondria or empty mitochondrial shells, and incorporating the same into mammalian cells via endocytosis. As such, effective functionality of exogenous mitochondria in cells is realized. The synthetic mitochondrial DNA genes introduced according to the present disclosure can be stably expressed and effectively passaged. The method for introducing exogenous mitochondrial DNA into mammalian cells as disclosed herein may be used as a whole new mitochondrial molecular cloning means to perform site-directed mutagenesis, gene insertion, gene knockout, gene rearrangement, and the like in mitochondria. Therefore, any molecular cloning modification can be performed on a mammalian mitochondrial DNA, which is of great importance to therapeutic schemes of diseases derived from mitochondrial DNA mutations.

摘要翻译： 本公开内容提供了通过将外源性线粒体DNA引入线粒体或空线粒体壳而获得合成线粒体并通过内吞作用将其并入哺乳动物细胞的方式来制备具有外源性线粒体的细胞的方法。 因此，实现了细胞中外源性线粒体的有效功能。 根据本公开引入的合成线粒体DNA基因可以稳定表达并有效传代。 如本文所公开的，将外源线粒体DNA引入哺乳动物细胞的方法可以用作线粒体中进行定点诱变，基因插入，基因敲除，基因重排等的全新的线粒体分子克隆方法。 因此，可以对哺乳动物线粒体DNA进行任何分子克隆修饰，这对于源自线粒体DNA突变的疾病的治疗方案是非常重要的。

公开(公告)号：EP2746283A1

公开(公告)日：2014-06-25

申请号：EP11867338.3

申请日：2011-12-21

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： DING, Ke ,  CHANG, Shaohua ,  XU, Shilin ,  ZHANG, Lianwen ,  TU, Zhengchao ,  DING, Jian ,  GENG, Meiyu ,  CHEN, Yi

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/541 ,  A61P35/00 ,  A61P35/02

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551

摘要： A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly can inhibit tumor cells with single or multiple mutations of EGFR (T790M). Therefore, the compound can be used as EGFR inhibitor to treat cancer and has a relatively large application value.

摘要翻译： 公开了式（I）或（II）的化合物和该化合物在制备用于治疗癌症的药物中的用途。 研究表明，该化合物可抑制多种肿瘤细胞的生长，可用于靶向表皮生长因子受体（EGFR），特别是可以用EGFR或T790M单突变或多重突变抑制肿瘤细胞。 因此，该化合物可用作EGFR抑制剂治疗癌症，具有较大的应用价值。

公开(公告)号：EP2481795A1

公开(公告)日：2012-08-01

申请号：EP11152519.2

申请日：2011-01-28

申请人： Universität für Bodenkultur Wien ,  Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： Esteban, Miguel ,  Grillari, Johannes ,  Grillari, Regina ,  Pei, Duanqing ,  Zhou, Ting

IPC分类号： C12N5/074

CPC分类号： C12N5/0696 ,  C12N2506/25

摘要： Methods for generating iPSCs and differentiated cells of interest by reprogramming donor cells that have been obtained in a non-invasive manner. In particular, the donor cells are exfoliated urine cells. The differentiated cells can be obtained by differentiation of the reprogrammed iPSCs or by direct reprogramming of the urine cells.

摘要翻译： 通过重新编程以非侵入性方式获得的供体细胞产生iPSC和分化细胞的方法。 特别地，供体细胞是脱落的尿细胞。 分化的细胞可以通过重新编程的iPSC的分化或通过尿细胞的直接重新编程获得。

公开(公告)号：EP2821481B1

公开(公告)日：2017-04-19

申请号：EP13754150.4

申请日：2013-02-06

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： PAN, Guangjin ,  PEI, Duanqing ,  WANG, Lihui ,  WANG, Linli ,  XUE, Yanting

IPC分类号： C12N5/0797 ,  C12N5/10 ,  C12N5/079 ,  C12N5/0793 ,  C12M3/00 ,  C12Q1/02 ,  A61K35/30 ,  A61P25/00 ,  A61P25/28

CPC分类号： C12N5/0623 ,  A61K35/30 ,  C12N15/85 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/25

摘要： Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-² inhibitor, ROCK inhibitor and BMP inhibitor.